Vaccines, excellent real world data

Pfizer-BioNTech vaccine provides high levels of defense from the very first dose

BNT162b2 mRNA

Injection efficiency in medical care employee

Prospective mate research study of team going through routine asymptomatic screening.

The SIREN study

N = 29,378

2 weekly periods

Records signs, PCR and antibody examination outcomes

Asymptomatic and symptomatic infections

Threat proportions to compare time

Infection in unvaccinated and also immunized teams

Searchings For, 5th February 2021

Individuals that were antibody adverse on recruitment

A solitary dose of BNT162b2 vaccine, efficiency of 72%.

21 days after initial dose.

Rising to 86% seven days after 2 dosages.


Vaccine effectively prevents both symptomatic as well as asymptomatic infection in functioning age adults.

When the dominant variant in flow was B1.1.7, cohort was vaccinated.

Consistent information.

Israel, Norwich Medical School.

Pfizer COVID-19 BNT162b2 injection, after a single dosage, ‘real-world’.

At day 21.

Vaccination performance, 91%.

After day 21.

Remained at 90%.

Anticipated to last form 9 weeks to 6 months.

Vaccination effectiveness seems to be far better at decreasing serious illness that at minimizing light disease.

Public health Scotland.

Fourth week after first dosage, decreased danger of hospitalisation.

Pfizer, down 84% (n = 650,000).

Oxford-AstraZeneca, down 94% (n = 490,000).

Consolidated decrease in over 80s.

Vaccination connected with 81% decrease in hospitalisation danger in the fourth week.

Leave a Comment

Your email address will not be published. Required fields are marked *